Ardelyx

ARDX

Market cap $1.71B

Here is how Ardelyx (ARDX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue 1

The average of price targets set by Wall Street analysts indicates a potential upside of 92.1% in Ardelyx (ARDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Ardelyx (ARDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company presented data, including results from the first real-world study of XPHOZAH, at American Society of Nephrology's Kidney Week, currently underway in Houston.

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 4:30 pm GMT/11:30 am ET.

Ardelyx (ARDX) is rated BUY, driven by strong Q3 2025 results, led by IBSRELA's explosive growth and resilient pipeline. IBSRELA revenue surged 92% YoY, offsetting XPHOZAH's Medicare-related decline; management raised 2025 guidance and outlined long-term peak sales targets. ARDX maintains a robust cash position, near-breakeven operations, and strategic patent protection, supporting ongoing commercial and pipeline development.

Ardelyx shares surged on Friday after strong Q3 results and positive guidance, validating patience during previous setbacks. The company demonstrated resilience, with recent financial performance supporting what should be renewed investor confidence in ARDX. Updated analysis highlights Ardelyx's improving fundamentals and potential for further upside following the latest quarterly report.

WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that President and CEO, Mike Raab will participate in a fireside chat at the Wedbush Rewind ASN 2025 Conference on Monday, November 10, 2025 from 11:30 a.m. to 12:00 p.m. ET.

Ardelyx, Inc. ( ARDX ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Michael Raab - President, CEO & Director Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial & Operations Officer Conference Call Participants Christopher Raymond Joohwan Kim Roanna Ruiz Dennis Ding Thomas Matthew Caufield - H.C. Wainwright & Co, LLC, Research Division Joseph Thome - TD Cowen, Research Division Julian Harrison - BTIG, LLC, Research Division Aydin Huseynov - Ladenburg Thalmann & Co. Inc., Research Division Daz Patel Presentation Operator " Caitlin Lowie Vice President of Corporate Communications & Investor Relations " Michael Raab President, CEO & Director " Eric Foster Chief Commercial Officer " Justin Renz Chief Financial & Operations Officer " Christopher Raymond " Raymond James Joohwan Kim " Citi Roanna Ruiz " Leerink Partners Dennis Ding " Jefferiesruiz Thomas " Wedbush Securities Matthew Caufield H.C.